SIBCS 2025丨Jun-jie Li: Riding China’s Wave of Innovation—Leveraging the SIBCS Platform to Drive Comprehensive Advances in Breast Cancer Care

SIBCS 2025丨Jun-jie Li: Riding China’s Wave of Innovation—Leveraging the SIBCS Platform to Drive Comprehensive Advances in Breast Cancer Care

2025.12.09
The 20th Shanghai International Breast Cancer Symposium (SIBCS), jointly hosted by the Shanghai Anti-Cancer Association and the Breast Cancer Committee of the China Anti-Cancer Association, was held from November 13–15, 2025 in Shanghai. During the meeting, Professor Jun-jie Li from Fudan University Shanghai Cancer Center delivered a keynote lecture entitled “Two Decades of Shared Progress: The Journey of China’s Original Innovation and the Rise of SIBCS.” Following the presentation, Oncology Frontier interviewed Professor Li to further discuss the latest advances of China’s original innovative drugs in breast cancer, and to explore how SIBCS enables cross-generational academic exchange and fosters synergistic development between Chinese innovations and the SIBCS platform.
SIBCS 2025 | Professor Kun Wang: Precision Subtyping Drives a New Era of Neoadjuvant Therapy in Breast Cancer—Current Exploration and Future Outlook 

SIBCS 2025 | Professor Kun Wang: Precision Subtyping Drives a New Era of Neoadjuvant Therapy in Breast Cancer—Current Exploration and Future Outlook 

2025.12.09
 The 20th Shanghai International Breast Cancer Symposium (SIBCS), hosted by the Shanghai Anti-Cancer Association and the Breast Cancer Committee of the China Anti-Cancer Association, was held on November 13–15, 2025. During the “Hundred Schools of Thought” session, Professor Kun Wang from Guangdong Provincial People’s Hospital delivered an academic presentation titled “Guangdong Experience: Exploring Neoadjuvant Therapy in the New Era.” Following his talk, Oncology Frontier invited Professor Wang to elaborate on his team’s latest clinical progress in breast cancer neoadjuvant therapy, and to share his insights on the evolving role of ADCs and major challenges ahead. 
ESMO China–International Dialogue | Meeting at the Summit: How China’s Innovative ADCs sac-TMT and A166 Are Reshaping the Breast Cancer Treatment Landscape 

ESMO China–International Dialogue | Meeting at the Summit: How China’s Innovative ADCs sac-TMT and A166 Are Reshaping the Breast Cancer Treatment Landscape 

2025.12.08
 At the 2025 European Society for Medical Oncology (ESMO) Annual Congress, Chinese innovative drugs and clinical research drew global attention. During the meeting, Xichun Hu, Professor at Fudan University Shanghai Cancer Center, presented a Late-Breaking Abstract (LBA) detailing the pivotal phase III study in which China’s first original HER2-targeted antibody–drug conjugate (ADC), A166 (budotituzumab vedotin), successfully challenged T-DM1 in the second-line setting for HER2-positive breast cancer. Based on this study, A166 received approval from the National Medical Products Administration (NMPA) on October 17, 2025, bringing a new standard-of-care option to clinical practice. 
ILCA Roundtable | MDT: Optimizing HCC Treatment Strategies – Insights from the TALENT Series Studies

ILCA Roundtable | MDT: Optimizing HCC Treatment Strategies – Insights from the TALENT Series Studies

2025.12.01
In recent years, advances in systemic therapy have offered hope for advanced liver cancer patients, but traditional single treatments remain limited, highlighting the need for new approaches. Combining systemic therapy with local treatments has become a key trend, with multidisciplinary team (MDT) collaboration now a global standard. Experts from surgery, interventional radiology, oncology, and more work together to design optimal, personalized treatment plans—from diagnosis and strategy development to timing of therapy and long-term follow-up.